IDERHA is an open platform designed to enable connectivity, access, sharing, use and reuse of digital health data. Our policy recommendations will enhance regulatory and HTA decision making, facilitating access to digital health innovations for patients and health care professionals.
Transforming data into better healthcare

In recent years, there has been an exponential growth in the generation of data that could be harnessed for use in healthcare delivery and research. These data include readouts generated by digital technologies, patient reported outcome and experience measures, and results from clinical trials and routine clinical care. However, accessing, integrating and analysing these data to maximize their value for patient care and research is extremely challenging.

IDERHA (Integration of heterogenous Data and Evidence towards Regulatory & HTA Acceptance)

The project aims to create a scalable platform for the seamless integration or linkage of diverse data to support healthcare professionals, patients, and researchers with new capabilities to improve patient outcomes. The new platform will be based on the development of common standards and practices - reducing current disconnected information silos. This enables more personalized health care along the patient’s journey via data-driven tools and solutions. The consortium will, therefore, develop the first pan-European health data space, and through policy recommendations drive health data access and the acceptability of heterogeneous health research results for regulatory and Health Technology Assessment decision-making.

Lung cancer as EU’s key priority

IDERHA will focus on lung cancer, which is responsible for 20% of cancer-related deaths in Europe and one of the key priorities of the Europe Beating Cancer program.

The project will link and analyse diverse data of a lung cancer patient’s journey: from early screening of citizens at risk, to development of lung cancer, to remote monitoring of late-stage patients to enable better care in an at home setting. Ultimately, the platform and policy recommendations will be disease independent.

Accelerate policy development

To enable patients and health care providers to benefit from novel health solutions, IDERHA also seeks to accelerate policy development. Informed by patient needs, we will develop consensus recommendations for fully compliant health data access and sharing, as well as for the acceptability of heterogeneous health research results for regulatory and HTA decision-making. This may lead to a framework for data governance that can be used as a model globally.

‘IDERHA is a pioneering project focussed on creating health care solutions that integrate diverse health data, to bring improved care and treatments for patients.’

KEY FACTS

IDERHA leadership & management:
IDERHA is led by the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Johnson & Johnson Medical GmbH, part of Johnson & Johnson MedTech. The management team consists of Dr. Philip Gribbon (Fraunhofer ITMP) and Dr. Christian Mehlendyck MD (Johnson & Johnson MEDICAL GmbH).

Consortium partners:
33 academic, clinical, medtech, pharmaceutical, IT and patient advocacy organizations as well as public authorities from across the EU and the world.

Funding:
IDERHA is among the first projects funded through the EU Innovative Health Initiative (IHI), a public-private partnership (PPP) between the EU and the European life science industries. IDERHA’s total budget is € 42.7 mln (plus contributions from Associated Partners from Switzerland and the UK).

Duration:
IDERHA will run for 5 years, from 1 April 2023 - 31 March 2028.

More information:
info@iderha.org